The Committee for Medicinal Products for Human Use (CHMP), a committee of the European Medicines Agency, drafted the guideline on adjustment for baseline covariates in 2013. The guideline aims to clarify when and why baseline covariates should be included in the primary analysis that will be specified in the protocol, and how the results in the study report should be presented and interpreted.